




Mouse IgG Isotype Control

Cat. No.	Format	Size
0107-01	Purified (UNLB)	10 mg
0107-02	Fluorescein (FITC)	0.5 mg
0107-04	Alkaline Phosphatase (AP)	1.0 mL
0107-05	Horseradish Peroxidase (HRP)	1.0 mL
0107-08	Biotin (BIOT)	0.5 mg
0107-09	R-phycoerythrin (PE)	0.1 mg
0107-10	R-phycoerythrin-Texas Red® (PE/TXRD)	0.1 mg
0107-11	Allophycocyanin (APC)	0.1 mg
0107-13	Spectral Red® (SPRD)	0.1 mg
0107-14	Low Endotoxin, Azide-Free (LE/AF)	0.5 mg
0107-17	R-phycoerythrin-Cyanine 7 (PE/CY7)	0.1 mg
0107-18	Allophycocyanin-Cyanine 5.5 (APC/CY5.5)	0.1 mg
0107-19	Allophycocyanin-Cyanine 7 (APC/CY7)	0.1 mg



FLISA plate was coated with Goat Anti-Mouse IgG, Human ads-UNLB (SB Cat. No. 1030-01), Goat Anti-Mouse IgA-UNLB (SB Cat. No. 1040-01), and Goat Anti-Mouse IgM, Human ads-UNLB (SB Cat. No. 1020-01). Serially diluted Mouse IgG-APC (SB Cat. No. 0107-11) was captured and fluorescence intensity quantified.

Description

Isotype	Mouse IgG
Source	Normal mouse serum

Applications

Quality tested applications include –

FC ⁷⁻¹⁰
 ELISA ¹⁻⁶
 FLISA

Other referenced applications include –

IHC-PS ¹¹
 ICC ¹²
 WB ^{13,14}
 IP ^{15,16}
 ChIP ^{17,18}
 Block ^{19,20}
In vitro control ²²⁻²⁵
In vivo control ^{2,9,21}

Working Dilutions

Flow Cytometry	FITC and BIOT conjugates	≤ 1 µg/10 ⁶ cells
	PE, PE/TXRD, APC, SPRD, PE/CY7, APC/CY5.5, and APC/CY7 conjugates	≤ 0.1 µg/10 ⁶ cells
	For flow cytometry, the suggested use of these reagents is in a final volume of 100 µL	
ELISA	AP conjugate	1:500 – 1:5,000
	HRP conjugate	1:4,000 – 1:8,000
Other Applications	Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need.	

For Research Use Only. Not for Diagnostic or Therapeutic Use.

Handling and Storage

- The purified (UNLB) IgG is supplied as 10 mg of purified immunoglobulin in 2.0 mL of borate buffered saline, pH 8.2. *No preservatives or amine-containing buffer salts added.* Store at 2-8°C.
- The fluorescein (FITC) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The alkaline phosphatase (AP) conjugate is supplied as 1.0 mL in a stock solution of 50 mM Tris/1 mM MgCl₂/50% glycerol, pH 8.0, containing NaN₃ as preservative. Store at 2-8°C or long-term at -20°C.
- The horseradish peroxidase (HRP) conjugate is supplied as 1.0 mL in a stock solution of 50% glycerol/50% PBS, pH 7.4. *No preservative added.* Store at 2-8°C or long-term at -20°C.
- The biotin (BIOT) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The R-phycoerythrin (PE) and allophycocyanin (APC) conjugates are supplied as 0.1 mg in 1.0 mL of PBS/NaN₃ and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- The Spectral Red® (SPRD), R-phycoerythrin-Cyanine 7 (PE/CY7), R-phycoerythrin-Texas Red® (PE/txRD), allophycocyanin-Cyanine 5.5 (APC/CY5.5), and allophycocyanin-Cyanine 7 (APC/CY7) conjugates are supplied as 0.1 mg in 1.0 mL of PBS/NaN₃ and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- The low endotoxin, azide-free (LE/AF) antibody is supplied as 0.5 mg purified immunoglobulin in 1.0 mL of PBS. Contains no preservative; handle under aseptic conditions. Store at 2-8°C or aliquot into smaller volumes and store at -20°C. Avoid multiple freeze / thaw cycles.
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.

Warning

Some reagents contain sodium azide. Please refer to product specific SDS.

References

1. Kuklin N, Daheshia M, Karem K, Manickan E, Rouse BT. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization. *J Virol.* 1997;71:3138-45. (ELISA)
2. Cupples AL. Addition of an anti-DNA antibody enhances plasmid DNA vaccination against herpes simplex virus [thesis]. Knoxville (USA): University of Tennessee; 2004. (ELISA, *in vivo* control)
3. Genestier L, Taillardet M, Mondiere P, Gheit H, Bella C, Defrance T. TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses. *J Immunol.* 2007;178:7779-86. (ELISA)
4. Wang Y, Diamond B. B cell receptor revision diminishes the autoreactive B cell response after antigen activation in mice. *J Clin Invest.* 2008;118:2896-907. (ELISA)
5. Szymczak WA, Davis MJ, Lundy SK, Dufaud C, Olszewski M, Pirofski L. X-linked immunodeficient mice exhibit enhanced susceptibility to *Cryptococcus neoformans* infection. *Mbio.* 2013;4(4): e00265-13. (ELISA)
6. Mann JF, McKay PF, Fiserova A, Klein K, Cope A, Rogers P, et al. Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes. *J Virol.* 2014;88:6959-69. (ELISA)
7. Nataf S, Davoust N, Ames RS, Barnum SR. Human T cells express the C5a receptor and are chemoattracted to C5a. *J Immunol.* 1999;162:4018-23. (FC)
8. Butler JE, Moore MB, Presnell SR, Chan H, Chalupny NJ, Lutz CT. Proteasome regulation of ULBP1 transcription. *J Immunol.* 2009;182:6600-9. (FC)
9. O'Neill AF, Dearling JL, Wang Y, Tupper T, Sun Y, Aster JC, et al. Targeted imaging of Ewing sarcoma in preclinical models using a ⁶⁴Cu-labeled anti-CD99 antibody. *Clin Cancer Res.* 2014;20:678-87. (FC, *in vivo* control)
10. Silvescu CI, Sackstein R. G-CSF induces membrane expression of a myeloperoxidase glycovariant that operates as an E-selectin ligand on human myeloid cells. *Proc Natl Acad Sci USA.* 2014;111:10696-701. (FC)
11. Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, DeBenedetto A, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. *J Allergy Clin Immunol.* 2007;120:150-5. (IHC-PS)
12. Hauser SP, Waldron JA, Upuda KB, Lipschitz DA. Morphological characterization of stromal cell types in hematopoietically active long-term murine bone marrow cultures. *J Histochem Cytochem.* 1995;43:371-9. (ICC)
13. Lintomen L, Elsas MI, Maximiano ES, de Paula Neto HA, Joseph D, Vargaftig BB, et al. Allergic sensitization prevents upregulation of haemopoiesis by cyclo-oxygenase inhibitors in mice. *Br J Pharmacol.* 2002;135:1315-23. (WB)
14. Xu J, Cui G, Esmailian F, Plunkett M, Marelli D, Ardehali A, et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. *Circulation.* 2004;109:363-8. (WB)
15. Inagaki T, Iwaki S, Matsumura Y, Kawamura T, Tanaka T, Abe Y, et al. The FBXL10/KDM2B scaffolding protein associates with novel polycomb repressive complex-1 to regulate adipogenesis. *J Biol Chem.* 2015;290:4163-77. (IP)
16. Li G, Nguyen CC, Ryckman BJ, Britt WJ, Kamil JP. A viral regulator of glycoprotein complexes contributes to human cytomegalovirus cell tropism. *Proc Natl Acad Sci USA.* 2015;112:4471-6. (IP)
17. Breslin MB, Wang H, Pierce A, Aucoin R, Lan MS. Neurogenin 3 recruits CBP co-activator to facilitate histone H3/H4 acetylation in the target gene INSM1. *FEBS Lett.* 2007;581:949-54. (ChIP)
18. Tao Y, Sharif N, Zeng B, Cai Y, Guo Y. Lateral ventricle injection of orexin-A ameliorates central precocious puberty in rat via inhibiting the expression of MEG3. *Int J Clin Exp Pathol.* 2015;8:12564-70. (ChIP)
19. Bühring H, Battula VL, Tremel S, Schewe B, Kanz L, Vogel W. Novel markers for the prospective isolation of human MSC. *Ann N Y Acad Sci.* 2007;1106:262-71. (Block)
20. Saiya-Cork K, Collins R, Parkin B, Ouillette P, Kuizon E, Kujawski L, et al. A pathobiological role of the insulin receptor in chronic lymphocytic leukemia. *Clin Cancer Res.* 2011;17:2679-92. (Block)
21. Arumugam T, Deng D, Bover L, Wang H, Logsdon CD, Ramachandran V. New blocking antibodies against novel AGR2-C4.4A pathway reduce growth and metastasis of pancreatic tumors and increase survival in mice. *Mol Cancer Ther.* 2015;14:941-51. (*In vivo* control)
22. Nakajima H, Samaridis J, Angman L, Colonna M. Cutting edge: Human myeloid cells express an activating ILT receptor (ILT1) that associates with Fc receptor γ-chain. *J Immunol.* 1999;162:5-8. (*In vitro* control)
23. Milbauer LC, Enestein JA, Roney M, Solovey A, Bodempudi V, Nichols TC, et al. Blood outgrowth endothelial cell migration and trapping in vivo: a window into gene therapy. *Transl Res.* 2009;153:179-89. (*In vitro* control)
24. Gibb DR, Shikh ME, Kang D, Rowe WJ, El Sayed R, Cichy J, et al. ADAM10 is essential for Notch2-dependent marginal zone B cell development and CD23 cleavage in vivo. *J Exp Med.* 2010;207:623-35. (*In vitro* control)
25. Xu G, Wen X, Hong Y, Du H, Zhang X, Song J, et al. An anti-transferrin receptor antibody enhanced the growth inhibitory effects of chemotherapeutic drugs on human glioma cells. *Int Immunopharmacol.* 2011;11:1844-9. (*In vitro* control)
26. Phoelcharoen W, Bhoo SH, Lai H, Ma J, Arntzen CJ, Chen Q, et al. Expression of an immunogenic Ebola immune complex in *Nicotiana benthamiana*. *Plant Biotechnol J.* 2011;9:807-16. (Size exclusion chromatography control)

Spectral Red® is a registered trademark of Southern Biotechnology Associates, Inc.
Spectral Red® is a PE/CY5 tandem conjugate.
Cy™ is a trademark of Cytiva or one of its subsidiaries.

TB0107
07-Oct-21

Corporate Offices: 160 Oxmoor Blvd • Birmingham, AL 35209 • USA **Mailing Address:** P.O. Box 26221 • Birmingham, AL 35260 • USA

Tel: 205.945.1774 • U.S. and Canada: 800.722.2255 • Fax: 205.945.8768

Email: info@southernbiotech.com • Website: www.southernbiotech.com